{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:02:50Z","timestamp":1773252170643,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e36306","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:10:47Z","timestamp":1723605047000},"page":"e36306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma"],"prefix":"10.1016","volume":"10","author":[{"given":"F.","family":"Pellicioli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Sala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Colonese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Belloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.I.","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Canova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.L.","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.heliyon.2024.e36306_bib1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36306_bib2","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.heliyon.2024.e36306_bib3","series-title":"StatPearls. Treasure Island (FL)","article-title":"Malignant mesothelioma","author":"Jain","year":"2023"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e36306_bib4","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1002\/cam4.5915","article-title":"Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database","volume":"12","author":"Bou-Samra","year":"2023","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36306_bib5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/1759-7714.14827","article-title":"Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations","volume":"14","author":"Sejben","year":"2023","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36306_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12672-022-00579-x","article-title":"BAP1 in cancer: epigenetic stability and genome integrity","volume":"13","author":"Caporali","year":"2022","journal-title":"Discov Oncol"},{"key":"10.1016\/j.heliyon.2024.e36306_bib7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36306_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36306_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.21037\/tlcr.2018.05.07","article-title":"A randomized phase II study of pleurectomy\/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205)","volume":"7","author":"Raskin","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36306_bib10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtcvs.2018.10.039","article-title":"Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection","volume":"157","author":"Verma","year":"2019","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36306_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36306_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"vPeters","year":"2022","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.heliyon.2024.e36306_bib13","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36306_bib14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial","volume":"9","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"10026","key":"10.1016\/j.heliyon.2024.e36306_bib15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial [published correction appears in Lancet. 2016 Apr 2;387(10026):e24]","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36306_bib16","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36306_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36306_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36306_bib19","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36306_bib20","doi-asserted-by":"crossref","unstructured":"Canova S, Ceresoli GL, Grosso F, et al. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100644.","DOI":"10.1016\/j.esmoop.2022.100644"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e36306_bib21","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36306_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001252","article-title":"Living beyond expectations: a qualitative study into the experience of long-term survivors with pleural mesothelioma and their carers","volume":"9","author":"Johnson","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36306_bib23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2018.01.006","article-title":"Survival outcomes among lung cancer patients treated using a multidisciplinary team approach","volume":"19","author":"Bilfinger","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36306_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36306_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36306_bib26","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36306_bib27","first-page":"90","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"CTCAE versi\u00f3n 5.0. Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas. Actas Dermosifiliogr (Engl Ed)."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e36306_bib28","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.3390\/cancers14184415","article-title":"Malignant pleural mesothelioma: current understanding of the immune microenvironment and treatments of a rare disease","volume":"14","author":"Tedesco","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e36306_bib29","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36306_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jtho.2023.02.003","article-title":"Brief report: Canadian cancer trials group IND.227: a phase 2 randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171)","volume":"18","author":"Piccirillo","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36306_bib31","article-title":"BEAT-meso: a randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)\u2014results from the ETOP 13-18 trial","volume":"42","author":"Sanjay Popat","year":"2024","journal-title":"J. Clin. Orthod."},{"issue":"1093","key":"10.1016\/j.heliyon.2024.e36306_bib32","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180164","article-title":"Adverse effects and radiological manifestations of new immunotherapy agents","volume":"92","author":"Tang","year":"2019","journal-title":"Br. J. Radiol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36306_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/cdp.10278","article-title":"Assessing radiological response to immunotherapy in lung cancer: an evolving arena","volume":"4","author":"Rallis","year":"2024","journal-title":"Cancer Diagn Progn"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024123377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024123377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:44:51Z","timestamp":1773182691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024123377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024123377"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36306","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e36306"}}